脂必泰联合阿托伐他汀治疗冠心病合并高脂血症的效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Lipopitride combined with Atorvastatin in the treatment of patients with coronary heart disease with hyperlipidemia.Methods A total of 103 patients with coronary heart disease and hyperlipidemia admitted to People′s Hospital of Yunyang District in Shiyan City from July 2018 to July 2019 were selected,and they were divided into Atorvastatin group (n=51) and combined treatment group (n=52) by random digital table method.Atorvastatin group was treated with Atorvastatin orally in the basic treatment,the combined treatment group was treated with Lipopitride combined with Atorvastatin.The control conditions of total cholesterol (TC),triacylglycerol(TG),low-density lipoprotein cholesterol (LDL-C),high-density lipoprotein cholesterol (HDL-C) were compared between the two groups,the levels of hypersensitive C reactive protein (hs-CRP) before and after treatment were measured and compared between the two groups,the adverse reactions of patients during medication were observed.Results The TC、TG、LDL-C control compliance rates in the combined treatment group were higher than those in the atorvastatin group (P＜0.05).There was no significant difference in HDL-C control compliance rate between the two groups(P＞0.05).After treatment,the hs-CRP of both groups was lower than that before treatment,and the hs-CRP of the combined treatment group was lower than that of Atorvastatin group (P＜0.05).The total adverse reaction rate in the combined treatment group was 5.77%,which was lower than 19.61% in the Atorvastatin group (P＜0.05).Conclusion Patients with coronary heart disease and hyperlipidemia treated with Lipopitride combined with Atorvastatin can play a better lipid-lowering effect,improve their blood lipid indicators,and reduce hs-CRP levels.

Key words： Lipopitride Atorvastatin Combined therapy Coronary heart disease Hyperlipidemia Hypersensitive C reactive protein

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Cheng-long

Cite this article:

ZHANG Cheng-long. Effect of Lipidetine combined with Atorvastatin in the treatment of coronary heart disease with hyperlipidemia[J]. 中国当代医药, 2021, 28(1): 78-80.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I1/78

[7]	谭斌.阿托伐他汀钙片联合脂必泰治疗冠心病合并高脂血症的效果[J].当代医学，2020，22（3）：9-11.
[8]	林果为，王吉耀，葛均波.实用内科学[M].15 版.北京：人民卫生出版社，2017：114-118.
[9]	艾聪，李娟，张珊姗，等.辽宁农村地区2009～2015年冠心病死亡趋势及早死所致疾病负担研究[J].中华疾病控制杂志，2018，22（11）：1106-1109.
[1]	覃策，胡敏.重庆江北区居民冠心病流行病学调查及危险因素分析[J].医学临床研究，2018，35（8）：1653-1655.
[2]	钟雷.老年冠心病合并高脂血症的临床治疗及预后分析[J].中华全科医学，2014，12（4）：580-581，584.
[3]	倪凤元.不同剂量瑞舒伐他汀钙治疗老年冠心病合并高脂血症的疗效及安全性研究[J].基层医学论坛，2018，22（10）：1336-1337.
[4]	王新成，郭游行，惠会婷，等.血浆Lp-pLA2、cTnI、HCY 水平与冠心病合并高脂血症患者冠脉病变程度的相关性研究[J].实用预防医学，2019，26（2）：208-210.
[5]	廖衡，张金龙，盛儒丹，等.稳心调脂汤治疗冠心病合并高脂血症的临床观察[J].中国中医急症，2019，28（3）：493-496.
[6]	白明洁，崔大卫.脂必泰胶囊应用于高脂血症的临床效果及对血脂、hs-CRP 的影响[J].中西医结合心脑血管病杂志，2018，16（9）：1250-1252.
[10]	王晓宏.瑞舒伐他汀钙治疗老年冠心病合并高脂血症的疗效及安全性对比观察[J].中国医药指南，2018，16（10）：58-59.
[11]	谢军，褚玲，刘娟.血浆Hcy 及sdLDL 对冠心病合并高脂血症患者心血管事件发生预测价值[J].标记免疫分析与临床，2018，25（2）：253-257.
[12]	王志建.阿托伐他汀并脂必泰对冠心病高脂血症及hsCRP的疗效[J].心血管康复医学杂志，2013，22（4）：407-409.
[13]	陈波，罗俊超，王朝阳.脂必泰胶囊对高脂血症病人血脂及超敏C 反应蛋白的影响[J].中西医结合心脑血管病杂志，2016，14（4）：420-422.
[14]	刘育苗，杨晓强.脂必泰联合阿托伐他汀钙对冠心病患者血脂的影响[J].西部中医药，2018，31（12）：89-91.
[15]	卢婷，谭斌，邓婷婷，等.脂必泰联合阿托伐他汀治疗冠状动脉粥样硬化性心脏病合并高脂血症的疗效及对超敏C-反应蛋白水平的影响[J].中国基层医药，2019，26（24）：3022-3025.